Drawing for NANORISK

USPTO serial 77255521

NANORISK

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
MCDOWELL, MATTHEW J
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with NANORISK?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Tamsen V. Valoir

Willam J. Stahl nanoTox, Inc.P.O. Box 1548Austin, TX 78767UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
001Biological preparations for scientific research purposes, namely, biological tissues or cell lines for use in the identification or assessment of nanoscale materials or biological interactions with nanoscale materials; proteins, peptide substrates, or enzymes for use in the identification or assessment of nanoscale materials or biological interactions with nanoscale materials; chemical test kits containing biological tissues, cell lines, proteins, peptide substrates, or enzymes for use in the identification or assessment of nanoscale materials or biological interactions with nanoscale materials; chemical preparations for scientific analysis purposes, namely, reagents for use in the identification or assessment of nanoscale materials or biological interactions with nanoscale materials; test kits containing chemical reagents for non-medical purposes, namely, for use in the identification or assessment of nanoscale materials or biological interactions with nanoscale materials; chemical preparations for scientific purposes, namely, chemical formulations for the solubilization, stabilization, or activation of nanoscale materials for use in presentation of nanoscale materials to various biological, physical, or chemical test systems to facilitate identification or assessment of nanoscale materials or biological interactions with nanoscale materials; diagnostic preparations for scientific useACTIVE—
005Biological diagnostic preparations for medical analysis use; chemical preparations for medical use, namely, chelators and scavengers for removing or diagnosing toxic nanoparticles; diagnostic preparations for medical useACTIVE—
009Software programs and downloadable software programs for use in risk assessment of nanomaterials, nanodevices and toxicology; scientific apparatus, instruments and devices for research and examination purposes, namely, lab-on-a-chip devices comprising microfluidics for use in the identification or assessment of nanoscale materials or biological interactions with nanoscale materials; gene microarrays comprising of oligo nucleotides for use in the identification or assessment of nanoscale materials or biological interactions with nanoscale materials; biosensors using chemical, electrochemical, biochemical, enzymatic, chromatographic, spectroscopic, or mass spectral detection methods for use in the identification or assessment of nanoscale materials or biological interactions with nanoscale materials; computers programmed with relational or expert databases of nanoscale material identification or assessment information for use in identification or assessment of nanoscale materials or biological interactions with nanoscale materials; laboratory equipment, measuring apparatus and instruments, namely, nanoscale material generation systems for introduction of nanoscale materials into physical, chemical, biochemical, or biological test systems comprised of dust generators for generating in vitro and in vivo exposures to nanoparticulates for inhalation exposures at toxicologic, pharmacologic, or therapeutic airborne concentrations, vaporizers, nebulizers and sprayers all for use in generating in vitro and in vivo exposures to droplets and other particles containing nanomaterials for inhalation exposures at toxicologic, pharmacologic or therapeutic concentrations, mixers for preparing test materials in solution, semi-solids or solids for exposures or doses of nanomaterials in vitro or in vivo experimental tests of a biological or clinical nature, incubators for creating and maintaining controlled test environments; pipettors, disposable syringes and containers and containment devices designed to retain, and deliver nanomaterials in liquid, semi-solid or solid dosage forms and for chemical analysis of dosage forms and biological samples from toxicologic or pharmacologic exposures in vitro and in vivo, and microplates designed to contain nanomaterials to avoid physicochemical, chemical, physical or electromagnetic effects that would interfere with precise measurements of toxicologic or pharmacologic endpoints; photometric test systems for use in the identification or assessment of nanoscale materials comprised of microplate readers, photomicroscopes, uv/vis photometers and photometric detectors, infrared photometers, photometric detectors, x-ray, gamma-ray, photo fluorescence and magnetic resonance imaging equipment; environmental sampling devices or systems for use in the identification or assessment of nanoscale materials or biological interactions with nanoscale materials comprised of dust and particulate impact collectors, electrostatic precipitators, water filtration collectors, centrifugal collection devices, air filtration devices and collectors, size exclusion separators, mass spectrometric air sampling systems comprised of mass selective or multiple detectors; photometric air and water sampling systems comprised of air or water sampling chambers with infrared, visible, ultraviolet, fluorescent or laser photometric means of nanoparticulate detection, x-ray diffraction and x-ray fluorescence sampling systems comprised of a variable x-ray source, nanomaterials containment or targeting device and an x-ray detector, liquid and chromatographic sampling systems comprised of an electronically or hydraulically controlled liquid sampling loop to deliver nanomaterials and a microprocessor-controlled microplate or vial in rack-type sample collector; all of the above goods are intended for scientific and laboratory research purposes and not medical purposesACTIVE—
041Teaching, training and educational services, namely, classes, seminars, workshops in the field of risk assessment of nanomaterials, nanodevices and toxicologyACTIVE—
042Scientific research and development for others in the fields of life sciences, biotechnology, toxicology, and genomics; chemical and toxicological analysis service; computer services, namely, providing online databases and websites featuring reports in the field of risk assessment of nanomaterials, nanodevices and toxicologyACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (ARAA): This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.

DateCodeEventWhat it means
Jul 22, 2010ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jul 22, 2010REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Jun 28, 2010MAB6ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Jun 28, 2010ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Jan 28, 2010EX2GSOU EXTENSION 2 GRANTED—
Jan 13, 2010AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Nov 23, 2009EXT2SOU EXTENSION 2 FILED—
Nov 23, 2009EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
May 25, 2009EX1GSOU EXTENSION 1 GRANTED—
May 25, 2009EXT1SOU EXTENSION 1 FILED—
May 25, 2009EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Nov 25, 2008NOAMNOA MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Sep 2, 2008PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Aug 13, 2008NPUBNOTICE OF PUBLICATION—
Jul 28, 2008PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Jul 24, 2008CNEAEXAMINERS AMENDMENT MAILED—
Jul 24, 2008CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jul 24, 2008XAECEXAMINER'S AMENDMENT ENTERED—
Jul 24, 2008CNEAEXAMINERS AMENDMENT -WRITTEN—
Jul 1, 2008ZZZXPREVIOUS ALLOWANCE COUNT WITHDRAWN—
Jun 27, 2008PBCRWITHDRAWN FROM PUB - OG REVIEW QUERY—
Jun 18, 2008PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Jun 18, 2008ALIEASSIGNED TO LIE—
Jun 18, 2008CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jun 16, 2008CNEAEXAMINERS AMENDMENT MAILED—
Jun 13, 2008XAECEXAMINER'S AMENDMENT ENTERED—
Jun 13, 2008CNEAEXAMINERS AMENDMENT -WRITTEN—
May 19, 2008TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
May 19, 2008CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
May 19, 2008TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 20, 2008ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 20, 2008REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Nov 26, 2007CNRTNON-FINAL ACTION MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 24, 2007CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 23, 2007DOCKASSIGNED TO EXAMINER—
Aug 20, 2007NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance